RZL-012 50mg/ml for Flank Mass

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Luxurgery, New York, NY
Flank Mass
RZL-012 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

A total of 12 subjects will be injected with RZL-012 and placebo. Each of the subject's flanks will be randomized for each of the treatment. A total of 24 flanks will be randomized in the double blind phase. They will be monitored for safety and efficacy for 12 weeks. After codes opening, a second treatment cycle on the previously untreated contralateral flank will be done. Subjects will be monitored for safety and efficacy for additional 12 weeks.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Flank Mass

Study Objectives

1 Primary · 5 Secondary · Reporting Duration: 30 hours

12 weeks
Efficacy - Change in satisfaction score
Efficacy - Change in score according Physician Global Assessment Scale
Efficacy - fat volume change
Efficacy -Change in fat volume
The incidence of Treatment-related Adverse Events [AEs]
30 hours
Pharmacokinetics measure - drug concentration in the blood (ng/mL)

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Other trials for Flank Mass

Trial Design

2 Treatment Groups

RZL-012 50mg/ml
1 of 2
Placebo
1 of 2
Active Control
Non-Treatment Group

12 Total Participants · 2 Treatment Groups

Primary Treatment: RZL-012 50mg/ml · Has Placebo Group · Phase 2

RZL-012 50mg/ml
Drug
ActiveComparator Group · 1 Intervention: RZL-012 · Intervention Types: Drug
Placebo
Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 30 hours
Closest Location: Luxurgery · New York, NY
Photo of New York 1Photo of New York 2Photo of New York 3
2022First Recorded Clinical Trial
1 TrialsResearching Flank Mass
2 CompletedClinical Trials

Who is running the clinical trial?

Raziel Therapeutics Ltd.Lead Sponsor
8 Previous Clinical Trials
368 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You agree to maintain your weight by not making any changes in your diet.
You are male and you agree to use highly effective contraceptive methods, e.g
You are between the ages of 18 and 65 years, inclusive.
You have symmetrical appearance of right and left flanks.
You are willing to avoid strenuous exercise for seven (7) days post treatment.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.